Cover Image
市場調查報告書

貓過敏:開發平台分析

Cat Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246030
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
貓過敏:開發平台分析 Cat Allergy - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 32 Pages
簡介

貓過敏是對貓身上的過敏原產生的過敏反應。症狀有噴嚏和鼻涕、鼻塞、鼻塞造成的臉部疼痛、咳嗽、胸部壓迫感、呼吸急促、喘鳴、淚目、眼睛充血和發癢、皮疹、蕁麻疹等。

本報告提供貓過敏的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表,加上開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

貓過敏 概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • ALK-Abello A/S
  • Amgen Inc.
  • Biomay AG
  • Circassia Pharmaceuticals plc

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Allergen for Cat Allergy
  • Allergen for Cat Allergy
  • BM-36
  • Epsi-Gam
  • tezepelumab
  • Vaccine for Cat Allergy
  • Vaccine for Cat Allergy

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8385IDB

Summary

Global Markets Direct's, 'Cat Allergy - Pipeline Review, H2 2016', provides an overview of the Cat Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cat Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cat Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cat Allergy
  • The report reviews pipeline therapeutics for Cat Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cat Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Cat Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cat Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cat Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cat Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cat Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Cat Allergy - Overview
  • Cat Allergy - Therapeutics under Development by Companies
  • Cat Allergy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Cat Allergy - Products under Development by Companies
  • Cat Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Amgen Inc.
    • Biomay AG
  • Cat Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BM-36 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tezepelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Cat Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cat Allergy - Dormant Projects
  • Cat Allergy - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cat Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Cat Allergy - Pipeline by ALK-Abello A/S, H2 2016
  • Cat Allergy - Pipeline by Amgen Inc., H2 2016
  • Cat Allergy - Pipeline by Biomay AG, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cat Allergy - Dormant Projects, H2 2016
  • Cat Allergy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cat Allergy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top